Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFD Technologies Regulatory News (FDP)

  • This share is currently suspended. It was suspended at a price of 2,450.00
  • There is currently no data for FDP

Trading Update

4 Apr 2016 07:00

RNS Number : 9656T
First Derivatives PLC
04 April 2016
 

4 April 2016

 

First Derivatives plc

("FD" or the "Group")

 

Trading Update

 

FD (AIM: FDP.L, ESM: FDP.I), a leading provider of software and consulting services, announces continued strong trading in the second half of its financial year to 29 February 2016. As a result the Board now expects the financial performance for the full year to be comfortably ahead of current consensus forecasts of £109.5m of revenue and £22.1m of EBITDA.

 

Consulting

Consulting revenue continued to grow strongly in the second half driven by the Group's high level of contracted revenue and a number of important new customer wins. This included a number of projects where FD is to act as a strategic partner to assist major investment banks with change programmes. This is in line with our business model under which we seek to grow these initial wins into multi-year assignments.

 

Software

We continue to see strong demand in our traditional financial services market across our range of software products, signing a record number of contracts in the second half of our financial year. Due to the annual recurring nature of our software license contracts the full impact of these wins will be reflected in the financial year ended February 2017. Outside financial services, the Group continues to make good progress with potential customers and partners for its Kx technology products especially for digital marketing and sensor analytics applications.

 

 

Brian Conlon, Chief Executive Officer of FD, commented: "We have made strong progress over the course of the past year and are well placed to continue to do so. In consulting our increasing scale and breadth of expertise is enabling us to get involved earlier in the change lifecycle within our clients, leading to deeper and more strategic relationships. In software, our market-leading capability in analysing large volumes of data in real time is increasingly understood and as a result we have experienced an acceleration of contract wins during the past year. We look forward to updating shareholders further when we announce our full year results."

 

 

Enquiries

For further information please contact:

First Derivatives plc

Brian Conlon, Chief Executive Officer

Graham Ferguson, Chief Financial Officer

Ian Mitchell, Head of Investor Relations

+44(0)28 3025 2242

www.firstderivatives.com

 

 

Investec Bank plc (Nominated Adviser and Broker)

Dominic Emery

Carlton Nelson

Sebastian Lawrence

+44 (0)20 7597 4000

 

 

Goodbody (ESM Adviser and Broker)

Linda Hickey

Finbarr Griffin

+353 1 667 0420

 

 

Walbrook PR

Paul Cornelius / Nick Rome / Helen Cresswell / Sam Allen

 

+44 (0)20 7933 8780

 

 

About FD

FD is a global technology provider with 20 years of experience. The Group's Kx technology is used by some of the world's largest finance, technology and energy institutions. FD employs over 1,500 people worldwide and has operations in London, New York, Stockholm, Singapore, Hong Kong, Tokyo, Sydney, Palo Alto, Toronto, Philadelphia, Dublin, Belfast and its headquarters in Newry.

 

For further information, please visit www.firstderivatives.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUAOVRNNASRAR
Date   Source Headline
6th Jun 20177:00 amRNSEnterprise Securities Market Notice
2nd Jun 20179:56 amRNSAnnual Report 2016/17 and AGM Notice
30th May 20175:13 pmRNSDirector/PDMR Shareholding
30th May 20175:12 pmRNSDirector/PDMR Shareholding
30th May 20172:06 pmRNSIssue of Equity from exercise of Share Options
16th May 20177:00 amRNSFinal Results
15th May 20175:09 pmRNSAppointment and Directorate Change
24th Apr 20177:00 amRNSTrading Update and Notice of Results
3rd Apr 201710:28 amRNSTotal Voting Rights
20th Mar 20177:00 amRNSEnterprise Securities Market Notice
14th Mar 20174:39 pmRNSIssue of Equity
14th Mar 20177:00 amRNSCollaboration Agreement with Airbus
2nd Mar 20177:00 amRNSContract Win
28th Feb 201710:09 amRNSTotal Voting Rights
7th Feb 20177:00 amRNSEnterprise Securities Market Notice
1st Feb 20173:54 pmRNSIssue of Equity
30th Dec 201610:57 amRNSTotal Voting Rights
23rd Dec 20167:00 amRNSEnterprise Securities Market Notice
19th Dec 20164:06 pmRNSIssue of Equity
7th Dec 20161:26 pmRNSHolding(s) in Company
7th Dec 20167:00 amRNSEnterprise Securities Market Notice
1st Dec 20164:52 pmRNSIssue of Equity from exercise of Share Options
30th Nov 201612:21 pmRNSTotal Voting Rights
8th Nov 20167:00 amRNSEntry into Retail Analytics market
8th Nov 20167:00 amRNSEnterprise Securities Market Notice
3rd Nov 20164:21 pmRNSDirector/PDMR Shareholding
3rd Nov 20164:20 pmRNSDirector/PDMR Shareholding
3rd Nov 20164:19 pmRNSDirector/PDMR Shareholding
1st Nov 20166:13 pmRNSIssue of Equity
1st Nov 20167:00 amRNSHalf Yearly Report
19th Oct 20167:00 amRNSNotice of Interim Results
30th Sep 20169:53 amRNSTotal Voting Rights
14th Sep 20167:00 amRNSEnterprise Securities Market Notice
7th Sep 20162:15 pmRNSIssue of Equity from exercise of Share Options
29th Jul 20161:29 pmRNSTotal Voting Rights
20th Jul 20164:59 pmRNSDirector Shareholding - AMENDMENT
19th Jul 20165:03 pmRNSDirector Shareholding
12th Jul 20167:00 amRNSDirector/PDMR Shareholding
30th Jun 20168:05 amRNSTotal Voting Rights
23rd Jun 20162:06 pmRNSResult of AGM
15th Jun 20167:00 amRNSDirector/PDMR Shareholding
6th Jun 201612:00 pmRNSIssue of Equity from exercise of Share Options
3rd Jun 20163:45 pmRNSAnnual Report 2015/16 and AGM Notice
19th May 20165:11 pmRNSHolding(s) in Company
17th May 20167:00 amRNSFinal Results
13th May 20164:38 pmRNSDirectorate Change
27th Apr 20167:00 amRNSStrategic Partnership with Thomson Reuters
26th Apr 20167:00 amRNSNotice of Results
4th Apr 20167:00 amRNSTrading Update
31st Mar 20164:44 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.